Runa Capital

Runa Capital is an international early-stage venture firm investing in deep-tech, B2B software, and selectively in regulated industries including health technology and fintech. Stage focus is seed and Series A, with checks typically in the $1M to $7M range and the capacity to lead or co-lead. Healthcare exposure is opportunistic and concentrated in software, AI applied to clinical or operational workflows, and life-sciences tooling rather than therapeutics or devices. Physician founders building enterprise health AI, clinical NLP, life-sciences data platforms, or B2B software for healthcare buyers are the most plausible fit. Founders building therapeutics, devices, consumer wellness brands, or scaled growth-stage rounds should pitch elsewhere. Geographic posture is European and US-broad, with comfort across multiple jurisdictions. The realistic entry path is a warm introduction from a Runa portfolio CEO, a co-investing seed fund, or a European technical operator in the partner’s network. Runa partners are technical and prefer founders who can defend product architecture in detail; pitches built on TAM rather than defensible engineering will not survive first read. Founders should arrive with clear commercial signal, defended IP or technical moat, and an articulated international expansion plan. Treat Runa as a credible Series A lead for deep-tech and software-shape healthcare AI companies, particularly those with European technical centers of gravity.